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PGS2
ASSESSMENT OF THE UTILITY OF SALSALATE
WITHIN A COX-2 INHIBITOR CLINICAL USAGE
PROTOCOL
Boggie DT, Schaefer MG, DeLattre ML, Morreale AP,
Plowman BK
Veterans Affairs San Diego Healthcare System (119), San
Diego, CA, USA
OBJECTIVES: Prior to approval of COX-2 inhibitor
therapy, a trial of salsalate alone or combined with 
acetaminophen is recommended by local COX-2
inhibitor guidelines. Our objective is to assess the persis-
tence of therapy, safety, and healthcare resource utiliza-
tion of salsalate therapy in the context of COX-2 usage
guidelines. METHODS: Disapproved COX-2 requests
from September 2000 to September 2002 that were sub-
sequently prescribed salsalate were included for analysis.
The evaluation period extended six months from salsalate
initiation in each patient. After excluding patients
without baseline GI Risk Scores, 41 patients remained for
analysis. The primary efﬁcacy outcome was persistence of
salsalate therapy through the evaluation period. Those
who stopped therapy were categorized as having adverse
events or lack of efﬁcacy. The primary safety outcome
was number of adverse drug events. Baseline characteris-
tics of patients who discontinued salsalate and those who
persisted were compared by unpaired t-test. Healthcare
resource utilization for patients included in the analysis
will be presented. RESULTS: Patients had a mean age of
63 ± 13.5 years, mean GI risk score 18 ± 4.8, and mean
daily salsalate dose of 2.0 ± 0.8 grams. There were 
no statistically signiﬁcant differences in characteristics
between patients who discontinued salsalate therapy and
those that persisted. The majority of patients were treated
for osteoarthritis (51%) or chronic pain (44%). Eighteen
patients persisted with salsalate therapy at 6 months
(43.9%). Treatment was discontinued in 23 patients
(56.1%) with 5 patients experiencing adverse events
(12.2%). Adverse events reported were gastrointestinal
upset (7.3%), diarrhea (4.8%), and tinnitus (2.4%). Eigh-
teen patients discontinued salsalate due to lack of efﬁcacy
(43.9%). CONCLUSIONS: Within a COX-2 usage
guideline, approximately half of patients persisted on sal-
salate with few observed adverse events. The high dis-
continuation and low side effect rates may be attributable
to a lower mean daily dose of salsalate in our population.
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LOW DOSE ESOMEPRAZOLE (20MG) USE IN
GENERAL PRACTICE:A RETROSPECTIVE AUDIT
Hayes AK1, Hinkley K2, Emmas CE2
1Brighstone Surgery, Brighstone, Isle of Wight, United
Kingdom; 2AstraZeneca UK Ltd, Luton, Bedfordshire, United
Kingdom
OBJECTIVES: Esomeprazole is the ﬁrst proton pump
inhibitor (PPI) to show higher healing rates and faster 
sustained relief when compared to omeprazole and 
lansoprazole. Esomeprazole 20mg has been shown to be
effective in the long-term treatment of patients with gas-
troesophageal reﬂux disease (GORD). However there are
no published studies that assess the use of esomeprazole
in routine clinical practice in a UK primary care setting.
METHODS: A retrospective audit of practice records was
performed in a general practice that had made esomepra-
zole its PPI of choice in early 2001 to determine the clin-
ical and cost implications of the change. RESULTS: The
audit identiﬁed 180 patients previously on regular PPI
therapy who had commenced treatment with esomepra-
zole. One hundred ﬁfty patients were prescribed low dose
esomeprazole (20mg) at the time of their initial therapy
change and 146 of these patients were previously on a
standard/high dose PPI. After 6 months 137/146 (94%)
of these patients remained on esomeprazole 20mg. The
majority of patients had no speciﬁc diagnosis but had
been treated symptomatically. Reassuringly of those
patients who did have a speciﬁcally recorded diagnosis of
reﬂux oesophagitis or GORD 41/43 (95%) remained on
esomeprazole 20mg after 6 months. Prior to the change
in therapy to esomeprazole, only 4/180 (2%) of patients
were treated with a low dose PPI. Six months after their
ﬁrst prescription for esomeprazole, 142/180 (79%)
patients remained on esomeprazole 20mg and a further
5 patients were no longer being treated with any PPI. In
addition, savings in PPI costs achieved during the ﬁrst 6
months after the 146 patients’ changed from standard/
high dose PPI therapy to esomeprazole 20mg was £7222.
CONCLUSION: Changing the therapy of patients on
regular standard/high dose PPI to esomeprazole 20mg is
a successful strategy; with very few patients switching
back to a higher dose.
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EFFECT OF COMPETITION ON ANTIULCER-
GASTRIC-MEDICATION ACQUISITION COSTS
FOR THE MEDICAID PROGRAM
Guo JJ, Pasquale MK, Cluxton RJ, Moomaw CJ,
Zimmerman J, Patel A, Heaton PC, Kelton CML
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: To determine the effect of generic drug
competition and new brand product entry on drug acqui-
sition costs for Medicaid. METHODS: Using the Ohio
Medicaid pharmacy claims database, we construct quar-
terly per-prescription reimbursement ﬁgures for each of
the individual brand-name and generic antiulcer gastric
medications (i.e., proton pump inhibitors (PPIs), H2
antagonists, and Carafate) from quarter 1, 1997, through
quarter 3, 2002. The drug acquisition cost for each
generic and brand-name drug is calculated as the per-
prescription reimbursement less an estimate of the Med-
icaid rebate per prescription using the rules as explained
in a recent Kaiser Commission report. A pooled cross-
section, time-series regression model is estimated using
